Astrazeneca Ab

Lanna Li

Robert Andrew Judkins

Eva-Lotte Lindstedt Alstermark

Anna Christina Olsson

Marianne Swanson

Anders Broo

Pernilla Sandberg

Kay Brickmann

Patrik Holm

Eva-Lotte Lindstedt-Alstermark

Lars Anders Mikael Johansson

Eva-Lotte Alstermark Lindstedt

Lars Weidolf

Carl-Johan Aurell

Tord Bertil Inghardt

Sverker Von Unge

Kjell Andersson

Maria Boije

Johan Gottfries

Anna Minidis

Jonas Boström

Christer Ralf Westerlund

Carl Anders Hogner

Jonas F&auml;gerhag

Björn Christian Ingvar Löfberg

Esmail Yousefi-Salakdeh

Mikael Ulf Johan Dahlström

Jonas Fagerhad

Lindstedt Alstermark Eva-Lotte

Krister Bamberg

Marlene Fredenwall

Susanne Doris Margit Bökman-Winiwarter

Disclosed herein are azetidinyl compounds of formula I, as described herein, pharmaceutical compositions comprising an azetidinyl compound, and a method of using an azetidinyl compound in the treatment or prophylaxis of a melanin-concentrating hormone related disease or condition.

(3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds

Disclosed herein are compounds of formula I in which R, R, R, R, R, A, X, Y are as described in the specification, their use in pharmaceutical compositions and in methods of treatment or prophylaxis of a melanin-concentrating hormone related disease or condition.

Therapeutic agents 713

The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) &#x3b1; (NR1H3) and/or &#x3b2; (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them. 

Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators

The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) &#x3b1; (NR1H3) and/or &#x3b2; (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

[object Object]

A compound of formula (I) wherein Rrepresents aryl optionally substituted by a heterocyclic group or a heterocyclic group optionally substituted by aryl wherein each aryl or heterocyclic group is optionally substituted; the group &#x2014;(CH)-T-(CH)&#x2014;U&#x2014;(CH&#x2014; is attached at either the 3 or 4 position in the phenyl ring as indicated by the numbers in formula (I) and represents a group selected from one or more of the following: O(CH), O(CH), NC(O)NR(CH), CHS(O)NR(CH), CHN(R)C(O)CH, (CH)N(R)C(O)(CH), C(O)NRCH, C(O)NR(CH), and CHN(R)C(O)CHO; V represents O, S, NRor a single bond; q represents 1, 2, or 3; W represents O, S, N(R)C(O), NR, or a single bond; Rrepresents halo, a Calkyl group which is optionally substituted by one or more fluoro, a Calkoxy group which is optionally substituted by one or more fluoro, a Cacyl group, aryl, an aryl Calkyl group, CN or NO; r represents 0, 1, 2 or 3; Rhalo, a Calkyl group which is optionally substutited by one or more fluoro, a Calkoxy group which is optionally substituted by one or more fluoro, a Cacyl group, aryl, an aryl Calkyl group, or CN; s represents 0, 1, 2 or 3; and R, R, R, R, R, R, and Rindependently represent H, a Calkyl group, aryl or an aryl Calkyl group or when m is O and T represents a group N(R)C(O) or a group (R)NS(O) then Rand Ror Rand Rtogether with the nitrogen atom to which they are attached represent a heteroaryl group; with provisos and pharmaceutically acceptable salts thereof, processes for preparing such compounds, their utility in treating clinical conditions associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.

Benzoic acid derivatives as modulators of PPAR alpha and gamma

The present invention provides the S enantiomer of a compound of formula (I) wherein n is 1 or 2 as well as pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs thereof, to processes for preparing such compounds, to their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them. 

Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor &#x3b1; (PPAR)

The present invention provides a compound of formula I processes for preparing such compounds, their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.

Therapeutic agents

The present invention provides the S enantiomer of a compound of formula I wherein Rrepresents chloro, trifluoromethyl or trifluoromethoxy, Rrepresents H or fluoro and Rrepresents a Calkyl group as well as pharmaceutically acceptable salts, solvates and prodrugs thereof, to processes for preparing such compounds, to their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.

The present invention provides a compound of formula (I), wherein n is 0, 1 or 2 and Rrepresents halo, a Calkyl group which is optionally substituted by one or more fluoro, a Calkoxy group which is optionally substituted by one or more fluoro and wherein when n is 2 the substituents Rmay be the same or different; Rrepresents a Calkyl group which is optionally interrupted by oxygen; Y is absent or represents methylene; and X is O or S; and pharmaceutically acceptable salts and prodrugs thereof, to processes for preparing such compounds, to their utility in treating clinical conditions associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them 

Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance

The present invention provides a compound of formula (I), wherein n is 0, 1 or 2; Rrepresents halo, a Calkyl group which is optionally substituted by one or more fluoro, a Calkoxy group which is optionally substituted by one or more fluoro and wherein when n is 2 the substituents Rmay be the same or different; Rrepresents an unbranched Calkyl group; Rrepresents H or OCH; and W represents O or S and pharmaceutically acceptable salts and prodrugs thereof, to processes for preparing such compounds, to their utility in treating clinical conditions associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.

The present invention provides the S enantiomer of a compound of formula (I); wherein Rrepresents 2,4-difluorophenyl or cyclohexyl as well as pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs thereof, to processes for preparing such compounds, to their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor &#x3b1;(PPAR)

The present invention relates to certain phenalkyloxy-phenyl derivatives of formula (I) and analogs, to a process for preparing such compounds, having the utility in clinical conditions associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Phenylalkyloxy-phenyl derivatives

The present invention releates to certain novel guanidine or amidine acid derivatives and analogs, to a process for preparing such compounds, having the utility in clinical conditions associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Guanidine and amidine acid derivatives and analogs and methods of using the same

Novel 3-aryl propionic acid derivatives and analogs, process and intermediate for their manufacture, pharmaceutical preparations containing them and the use of the compounds in clinical conditions associated with insulin resistance.

Growing community of inventors

Mölndal, Sweden

Lanna Li